Article
Biochemistry & Molecular Biology
Leticia Aptecar, Carole Puech, Evelyne Lopez-Crapez, Marion Peter, Peter Coopman, Veronique D'Hondt, Gilles Freiss
Summary: The expression level of PTPN13 gene is closely related to the prognosis of HGSOC. Knockout/silencing of PTPN13 increases the migration and invasion ability of KURAMOCHI cells, as well as the expression of mesenchymal phenotype and EMT-related genes. In addition, overexpression of PTPN13 increases the sensitivity of HGSOC cells to platinum-containing drugs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Endocrinology & Metabolism
Laris Achlaug, Lina Somri-Gannam, Shilhav Meisel-Sharon, Rive Sarfstein, Manisha Dixit, Shoshana Yakar, Mordechai Hallak, Zvi Laron, Haim Werner, Ilan Bruchim
Summary: This study evaluated the expression of ZYG11A in EOC patients and found reduced ZYG11A expression in high grade tumors, suggesting a potential tumor suppressor role. The study also identified an inverse correlation between ZYG11A and p53 levels in individual tumors. Further exploration of ZYG11A as a novel biomarker in EOC is warranted based on these findings.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Multidisciplinary Sciences
He Li, Nayiyuan Wu, Zhao-Yi Liu, Yong-Chang Chen, Quan Cheng, Jing Wang
Summary: This study highlights the important roles of transcription factors (TFs) in serous ovarian cancer (SOC) and develops a 17-TFs related prognostic signature to accurately predict the survival of SOC patients. Analysis of immune infiltration and treatment responses show significant differences between high-risk and low-risk groups, providing insights for personalized therapy.
SCIENTIFIC REPORTS
(2021)
Article
Reproductive Biology
Yan Rong, Li Li
Summary: The study evaluated the clinical value of early clearance of HE4 and CA125 in predicting platinum sensitivity and prognosis in patients with ovarian cancer. The results showed that early clearance of HE4 and CA125 could predict platinum response and prognosis, aiding in predicting the risk of progression and relapse.
JOURNAL OF OVARIAN RESEARCH
(2021)
Article
Reproductive Biology
Zhen Yuan, Ying Zhang, Dongyan Cao, Keng Shen, Qingshui Li, Guonan Zhang, Xiaohua Wu, Manhua Cui, Ying Yue, Wenjun Cheng, Li Wang, Pengpeng Qu, Guangshi Tao, Jianqing Hou, Lixin Sun, Yuanguang Meng, Guiling Li, Changzhong Li, Huirong Shi, Yaqing Chen
Summary: This study evaluated the efficacy and safety of PLD in treating platinum-resistant and platinum-refractory relapse in patients with epithelial ovarian, fallopian tube, and peritoneal cancer. The results showed that PLD was associated with satisfactory efficacy, low frequency of adverse events, and high patient quality of life, with low baseline CA125 levels and a reduction in CA125 after the first cycle predicting satisfactory efficacy.
JOURNAL OF OVARIAN RESEARCH
(2021)
Review
Radiology, Nuclear Medicine & Medical Imaging
Sofia Amante, Filipa Santos, Teresa Margarida Cunha
Summary: Low-grade serous carcinoma (LGSC) is a rare subtype of ovarian cancer, accounting for 5% of epithelial neoplasms, with distinct molecular features, pathogenesis, and clinical behavior compared to high-grade serous carcinoma (HGSC). LGSC typically presents as mixed lesions with different proportions of papillary projections and solid components, distinguishable from other ovarian serous tumors, and imaging plays a crucial role in differentiation and diagnosis.
INSIGHTS INTO IMAGING
(2021)
Article
Oncology
Thomas Bartl, Jasmine Karacs, Caroline Kreuzinger, Stephanie Pfaffinger, Jonatan Kendler, Cristina Ciocsirescu, Andrea Wolf, Alexander Reinthaller, Elias Meyer, Maximilian Brandstetter, Magdalena Postl, Eva Langthaler, Elena Braicu, Ignace Vergote, Paula Cunnea, Charlie Gourley, Wolfgang D. Schmitt, Dan Cacsire Castillo-Tong, Grimm Christoph
Summary: Utilizing CA-125 levels to estimate tumor growth rate can be a valuable tool in predicting treatment response and survival of patients with recurrent high-grade serous ovarian cancer.
Article
Oncology
Hong Zheng, Tong Shu, Shan Zhu, Chao Zhang, Min Gao, Nan Zhang, Hongguo Wang, Jie Yuan, Zaixian Tai, Xuefeng Xia, Yuting Yi, Jin Li, Yanfang Guan, Yang Xiang, Yunong Gao
Summary: This study aimed to predict platinum sensitivity in epithelial ovarian cancer after initial cytoreductive surgery by integrating novel biomarkers and using next generation sequencing to analyze genomic features of ovarian tumors obtained from surgery. Specific genetic features such as positive SBS10a signature, FAM175A LOH, and negative WGD were significantly associated with platinum-sensitive patients, leading to longer progress-free survival. A lasso regression model incorporating these biomarkers showed high accuracy in predicting platinum sensitivity, which was further validated in an independent cohort from the TCGA dataset.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Ruilin Lei, Yunfang Yu, Qingjian Li, Qinyue Yao, Jin Wang, Ming Gao, Zhuo Wu, Wei Ren, Yujie Tan, Bingzhong Zhang, Liliang Chen, Zhongqiu Lin, Herui Yao
Summary: The study aimed to develop and validate a deep learning model to predict platinum sensitivity in patients with epithelial ovarian cancer using MRI. The results showed that the whole abdomen model performed better than the primary tumor model and successfully discriminated high- and low-risk recurrence patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Federica D'Amico, Anna Myriam Perrone, Simone Rampelli, Sara Coluccelli, Monica Barone, Gloria Ravegnini, Marco Fabbrini, Patrizia Brigidi, Pierandrea De Iaco, Silvia Turroni
Summary: This pilot study on the trajectory of gut microbiota in patients with epithelial ovarian cancer undergoing chemotherapy found distinct changes in the microbiota of platinum-resistant patients, potentially linked to therapeutic failure. In contrast, platinum-sensitive patients showed more diverse and stable microbiota, which may be beneficial for treatment.
Article
Biochemistry & Molecular Biology
Horacio Cardenas, Fang Fang, Guanglong Jiang, Susan M. Perkins, Chi Zhang, Robert E. Emerson, George Hutchins, Harold N. Keer, Yunlong Liu, Daniela Matei, Kenneth Nephew
Summary: This study investigated the impact of DNA methylation on the initiation and progression of high-grade serous ovarian cancer (HGSOC), as well as its association with platinum resistance. The findings suggest potential roles for hypomethylating agents in treating HGSOC, providing important insights into the epigenetic landscape of HGSOC tumorigenesis and potential therapeutic strategies.
Article
Oncology
Wenwen Guo, Xue He, Jing Ni, Liya Ma, Xianzhong Cheng, Congyang Wang, Xiaoxiang Chen, Yan Wang
Summary: This study identified differential protein expression profiles between platinum-sensitive and platinum-resistant patients in HGSOC, with enrichment of ECM-related proteins in the platinum-sensitive group. SERPINA10 was found to be positively correlated with survival outcomes and demonstrated potential as a biomarker for predicting response and survival in platinum-based chemotherapy of HGSOC.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Guonan Zhang, Jie Zhang, Yi Zhu, Hong Liu, Yu Shi, Kun Mi, Meiying Li, Qi Zhao, Ziyi Huang, Jianming Huang
Summary: Somatic mutations in the BRCA2 BRC domain are associated with increased sensitivity to platinum-based therapy and improved survival outcomes in high-grade serous ovarian cancer.
EXPERIMENTAL CELL RESEARCH
(2021)
Article
Oncology
Haonan Lu, Paula Cunnea, Katherine Nixon, Natasha Rinne, Eric O. Aboagye, Christina Fotopoulou
Summary: This study identified ALG5 as a potential prognostic biomarker for early tumor progression in advanced HGSOC patients despite CGR, with high expression of ALG5 associated with poor prognosis. Mechanistically, ALG5 was found to be linked to oxidative phosphorylation pathway.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Claudia Marchetti, Francesca De Felice, Alessia Romito, Valentina Iacobelli, Carolina Maria Sassu, Giacomo Corrado, Caterina Ricci, Giovanni Scambia, Anna Fagotti
Summary: Ovarian cancer is a fatal malignancy with most patients experiencing recurrent and chemotherapy-resistant disease. Understanding the complexity of platinum-resistant OC, identifying reliable biomarkers, and developing innovative therapies are crucial in improving management. Efforts to overcome platinum resistance in OC represent a dynamic field with rapidly developing drugs and clinical trials.
SEMINARS IN CANCER BIOLOGY
(2021)
Article
Oncology
Christian Marth, Rafal Tarnawski, Alexandra Tyulyandina, Sandro Pignata, Lucy Gilbert, Diego Kaen, M. Jesus Rubio, Sophia Frentzas, Mario Beiner, Manuel Magallanes-Maciel, Laura Farrelly, Chel Hun Choi, Regina Berger, Christine Lee, Christof Vulsteke, Kosei Hasegawa, Elena Ioanna Braicu, Xiaohua Wu, Jodi McKenzie, John J. Lee, Vicky Makker
Summary: The combination of pembrolizumab plus lenvatinib has shown promising efficacy in treating advanced endometrial cancer patients, especially those who have had limited previous treatment. Randomized controlled trials have demonstrated that this combination therapy has superior outcomes in terms of objective response rates, progression-free survival, and overall survival compared to chemotherapy.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2022)
Article
Oncology
Sofya Marchenko, Iris Piwonski, Inga Hoffmann, Bruno Valentin Sinn, Catarina Alisa Kunze, Nanna Monje, Jonathan Pohl, Hagen Kulbe, Wolfgang Daniel Schmitt, Sylvia Darb-Esfahani, Elena Ioana Braicu, Ann-Christin von Bruenneck, Jalid Sehouli, Carsten Denkert, David Horst, Korinna Joehrens, Eliane Tabea Taube
Summary: The study found that higher proportions of regulatory T cells (Tregs) and lower ratios of T helper 17 cells (Th17 cells) were associated with better overall survival in high-grade serous tubo-ovarian carcinoma. This research is important for understanding the impact of the tumor microenvironment on tumor development.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Jacek Glajzer, Dan Cacsire Castillo-Tong, Rolf Richter, Ignace Vergote, Hagen Kulbe, Adriaan Vanderstichele, Ilary Ruscito, Fabian Trillsch, Alexander Mustea, Caroline Kreuzinger, Charlie Gourley, Hani Gabra, Eliane T. Taube, Oliver Dorigo, David Horst, Carlotta Keunecke, Joanna Baum, Timothy Angelotti, Jalid Sehouli, Elena Ioana Braicu
Summary: This study evaluates the impact of BRCA gene status on tumor dissemination, surgical outcome, and survival in ovarian cancer patients. BRCA mutation was associated with younger age, more extensive tumor involvement, higher debulking rates, and prolonged overall survival. The study suggests considering BRCA mutation status in patient selection for cytoreductive surgery.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Jana Ihlow, Nanna Monje, Inga Hoffmann, Philip Bischoff, Bruno Valentin Sinn, Wolfgang Daniel Schmitt, Catarina Alisa Kunze, Sylvia Darb-Esfahani, Hagen Kulbe, Elena Ioana Braicu, Jalid Sehouli, Carsten Denkert, David Horst, Eliane Tabea Taube
Summary: Recent advances in molecular medicine have highlighted the potential therapeutic targets of G-protein coupled receptors (GPCRs) in ovarian cancer, particularly the regulator of G protein signaling 2 (RGS2). This study retrospectively analyzed the expression and prognostic value of RGS2 in high-grade serous ovarian cancer (HGSOC). The results showed that low protein expression of RGS2 was associated with inferior overall survival and progression-free survival. Further exploration is needed to understand the functional role of RGS2 in HGSOC and its implications for new drug discovery.
Editorial Material
Oncology
Jacek Glajzer, Dan Cacsire Castillo-Tong, Rolf Richter, Ignace Vergote, Hagen Kulbe, Adriaan Vanderstichele, Ilary Ruscito, Fabian Trillsch, Alexander Mustea, Caroline Kreuzinger, Charlie Gourley, Hani Gabra, Eliane T. Taube, Oliver Dorigo, David Horst, Carlotta Keunecke, Joanna Baum, Timothy Angelotti, Jalid Sehouli, Elena Ioana Braicu
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Sara Nasser, Aygun Babayeva, Ioana Braicu, Rolf Richter, Esra Bilir, Radoslav Chekerov, Mustafa-Zelal Muallem, Klaus Pietzner, Melissa-Guelhan Inci, Jalid Sehouli
Summary: This prospective study analyzed the different features of peritoneal carcinomatosis in ovarian cancer patients and found that diffuse peritoneal localization was a significant predictor of recurrence. Lower OS and PFS rates were associated with diffuse peritoneal localization, wet PC, and additional lymph node involvement.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Lukas Chinczewski, Felix Wilhelm Feldhaus, Wolfgang Schmitt, Ioana Braicu, Eva Roser, Jalid Sehouli
Summary: This is a case report on a patient with Lynch syndrome-associated ovarian cancer (OC) who achieved a complete response to immunotherapy with pembrolizumab. The findings suggest that immune checkpoint inhibition is an effective therapy for Lynch syndrome-associated OC that is nonresponsive to standard treatment.
ANTICANCER RESEARCH
(2023)
Article
Oncology
Joanna Baum, Daniel Zickler, Juliane Bolbrinker, Rolf Richter, Elena Ioana Braicu, Jacek Grabowski, Jalid Sehouli
Summary: For patients with severe renal impairment or end-stage renal disease, the use of olaparib is not recommended due to lack of evaluation in this patient group. This study reports the pharmacokinetics, efficacy, safety, and tolerability of olaparib in a patient with recurrent epithelial ovarian cancer and end-stage renal disease undergoing hemodialysis.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2023)
Article
Oncology
Helmut Plett, Enzo Ricciardi, Vlad Vacaru, Jan Phillip Ramspott, Nicoletta Colombo, Jalid Sehouli, Andreas du Bois, Annalisa Garbi, Rolf Richter, Beyhan Ataseven, Giovanni Aletti, Elena Braicu, Florian Heitz, Rosalba Portuesi, Mustafa-Zelal Muallem, Timoleon Dagres, Gabriella Parma, Eva Roser, Alexander Traut, Francesco Multinu, Philipp Harter
Summary: This study aimed to analyze the clinicopathological parameters and their impact on progression-free and overall survival in patients with primary adult granulosa cell tumors. The prognosis of patients with primary adult granulosa cell tumors is mainly determined by the FIGO stage. Fertility-sparing surgery seems to be a safe procedure in FIGO IA stage, while adjuvant chemotherapy is not supported in early and advanced stages of adult granulosa cell tumors.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Oncology
Maximilian Klar, Helmut Plett, Philipp Harter, Florian Heitz, Stefan Kommoss, Andreas Daniel Hartkopf, Marcel Grube, Eva Roser, Jalid Sehouli, Iona Braicu, Bastian Czogalla, Alexander Burges, Michaela Bossart, Mir Fuad Hasanov, Teresa Link, Annette Staebler, Doris Mayr, Paul Buderath, Annette Hasenburg
Summary: This study aims to understand the treatment strategies and survival status of malignant sex cord-stromal cell tumors (SCST) and identify research needs. The findings show that although the recurrence rate is high, overall survival rates of SCST patients are excellent.
JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Sabine Heublein, Joanna Baum, Anna Jaeger, Donata Grimm-Glang, Julia Olthoff, Elena Ioana Braicu, Osama Azzam Nieto, Kathrin Hassdenteufel, Barbara Schmalfeldt, Lars Hanker, Markus Wallwiener, Andreas Schneeweiss, Jalid Sehouli, Klaus Pietzner
Summary: There is disagreement about the extent of surgical staging and the indication of adjuvant chemotherapy for patients with early-stage ovarian cancer (OC). This study revealed that a significant proportion of early-stage OC patients were not operated on according to the current standard, and highlighted the need for further prospective registries and educational programs to improve clinical management.
Article
Oncology
Wanja Kassuhn, Pedro R. Cutillas, Mirjana Kessler, Jalid Sehouli, Elena I. Braicu, Nils Bluethgen, Hagen Kulbe
Summary: High-grade serous ovarian cancer (HGSOC) is a highly lethal form of ovarian cancer with molecular heterogeneity. In this study, the mesenchymal subtype of HGSOC was characterized and targeted treatment opportunities were identified through bulk and single-cell RNA data analysis. The composition of tumor microenvironment, cell-cell communication, and transcription factor regulation were investigated to find potential therapeutic targets for personalized treatment.
Article
Oncology
I. Vergote, E. Van Nieuwenhuysen, A. Casado, A. Laenen, D. Lorusso, E. I. Braicu, E. Guerra-Alia, P. Zola, P. Wimberger, P. R. Debruyne, E. Falco, A. Ferrero, M. Z. Muallem, J. Kerger, E. Garcia-Martinez, S. Pignata, J. Sehouli, T. Van Gorp, C. Gennigens, M. J. Rubio
Summary: This study aimed to establish the role of nintedanib in first-line recurrent/metastatic cervical cancer. The results showed that nintedanib improved the progression-free survival compared to the carboplatin-paclitaxel group. The nintedanib group had a longer median overall survival and a higher RECIST response rate.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Obstetrics & Gynecology
M. Bossart, H. Plett, B. Kraemer, E. Braicu, B. Czogalla, M. Klar, S. Singer, D. Mayr, A. Staebler, A. du Bois, S. Kommoss, T. Link, A. Burges, F. Heitz, M. Grube, F. Trillsch, P. Harter, P. Wimberger, P. Buderath, A. Hasenburg
Summary: This study aimed to evaluate the anxiety and depression levels of survivors of malignant ovarian germ cell tumors (MOGCT) and sex cord stromal tumors (SCST), and to identify possible factors that could be modified. Multivariate linear regression analysis was used to investigate the effects of factors such as type of surgery, chemotherapy, time since diagnosis, recurrence, second tumor, and pain on anxiety and depression. The findings showed that fertility-conserving surgery was associated with lower levels of mental distress, while pain was associated with higher levels of distress.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
(2023)
Article
Oncology
Maria-Pilar Barretina-Ginesta, Bradley J. Monk, Sileny Han, Bhavana Pothuri, Annika Auranen, Dana M. Chase, Domenica Lorusso, Charles Anderson, Sophie Abadie-Lacourtoisie, Noelle Cloven, Elena Braicu, Amnon Amit, Andres Redondo, Ruchit Shah, Nehemiah Kebede, Carol Hawkes, Divya Gupta, Tatia Woodward, David M. O'Malley, Antonio Gonzalez-Martin
Summary: Maintenance treatment with niraparib in patients with advanced ovarian cancer leads to significant improvements in quality-adjusted progression-free survival and quality-adjusted time without symptoms of disease or toxicity compared to placebo.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)